EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs

Enric Monreal, José Ignacio Fernández-Velasco, María Isabel García-Sánchez, Susana Sainz de la Maza, Sara Llufriu, Roberto Álvarez-Lafuente, Bonaventura Casanova, Manuel Comabella, Lluís Ramió-Torrentà, José Enrique Martínez-Rodríguez, Luis Brieva, Albert Saiz und 16 weitere

JAMA Neurology · 2023

DOI: 10.1001/jamaneurol.2023.0010 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Neurology, 2023. Verfasst von Enric Monreal und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hospital Universitario Ramón y Cajal, La Red Española de Esclerosis Múltiple, Instituto Ramón y Cajal de Investigación Sanit…. Hauptthemen laut MEDLINE: Multiple Sclerosis. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The value of serum neurofilament light chain (sNfL) levels for predicting long-term disability in patients with multiple sclerosis (MS) remains controversial.

Objective

To assess whether high sNfL values are associated with disability worsening in patients who underwent their first demyelinating MS event. Design, Setting, and Participants This multicenter cohort study included patients who underwent their first demyelinating event suggestive of MS at Hospital Universitario Ramón y Cajal (development cohort; June 1, 1994, to September 31, 2021, with follow-up until August 31, 2022) and 8 Spanish hospitals (validation cohort; October 1, 1995, to August 4, 2020, with follow-up until August 16, 2022). Exposures Clinical evaluations at least every 6 months. Main Outcomes and Measures The main outcomes were 6-month confirmed disability worsening (CDW) and an Expanded Disability Status Scale (EDSS) score of 3. Levels of sNfL were measured in blood samples obtained within 12 months after disease onset using a single molecule array kit. The cutoffs used were sNfL level of 10 pg/mL and a standardized score ( z score) of 1.5. Multivariable Cox proportional hazards regression models were used to evaluate outcomes.

Results

Of the 578 patients included in the study, 327 were in the development cohort (median age at sNfL analysis, 34.1 years [IQR, 27.2-42.7 years]; 226 female [69.1%]) and 251 patients were in the validation cohort (median age at sNfL analysis, 33.3 years [IQR, 27.4-41.5 years]; 184 female [73.3%]). The median follow-up was 7.10 years (IQR, 4.18-10.0 years). Levels of sNfL greater than 10 pg/mL were independently associated with higher risk of 6-month CDW and an EDSS of 3 in the development cohort (6-month CDW: hazard ratio [HR], 2.39; 95% CI, 1.39-4.12; P = .002; EDSS of 3: HR, 4.12; 95% CI, 2.18-7.77; P < .001) and the validation cohort (6-month CDW: HR, 1.61; 95% CI, 1.07-2.42; P = .02; EDSS of 3: HR, 2.03; 95% CI, 1.23-3.33; P = .005). Highly effective disease-modifying treatments were associated with lower risks of 6-month CDW and an EDSS of 3 in patients with high baseline sNfL values. Conclusions and Relevance This cohort study found that high sNfL values obtained within the first year of disease were associated with long-term disability worsening in MS, suggesting that sNfL level measurement may help identify optimal candidates for highly effective disease-modifying treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisHumansFemaleAdultCohort StudiesIntermediate FilamentsTreatment OutcomeNeurofilament ProteinsBiomarkers

Substanzen

Neurofilament ProteinsBiomarkers

Autor:innen und Institutionen

  • Department of Neurology, Hospital Universitario Ramón y Cajal, La Red Española de Esclerosis Múltiple, Instituto Ramón y Cajal de Investigación Sanitaria, Universidad de Alcalá, Madrid, Spain.
  • Department of Immunology, Hospital Universitario Ramón y Cajal, La Red Española de Esclerosis Múltiple, Instituto Ramón y Cajal de Investigación Sanitaria, Universidad de Alcalá, Madrid, Spain.
  • Nodo Biobanco Hospital Virgen Macarena (Biobanco del Sistema Sanitario Público de Andalucía), Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer and Universitat de Barcelona, Barcelona, Spai…
  • Grupo Investigación de Factores Ambientales en Enfermedades Degenerativas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain.
  • Multiple Sclerosis and Neuroimmunology Research Group, Fundación para la Investigación La Fe, Valencia, Spain.

Zitieren

APA

Monreal, E., Fernández-Velasco, J. I., García-Sánchez, M. I., Sainz de la Maza, S., Llufriu, S., Álvarez-Lafuente, R., Casanova, B., Comabella, M., Ramió-Torrentà, L., Martínez-Rodríguez, J. E., Brieva, L., Saiz, A., Eichau, S., Cabrera-Maqueda, J. M., Villarrubia, N., Espiño, M., Pérez-Miralles, F., Montalbán, X., Tintoré, M., …, & Villar, L. M. (2023). Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2023.0010

Vancouver

Monreal E, Fernández-Velasco JI, García-Sánchez MI, Sainz de la Maza S, Llufriu S, Álvarez-Lafuente R, et al. Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs. JAMA Neurology. 2023. doi:10.1001/jamaneurol.2023.0010

BibTeX
@article{Monreal2023,
  author = {Monreal, Enric and Fernández-Velasco, José Ignacio and García-Sánchez, María Isabel and Sainz de la Maza, Susana and Llufriu, Sara and Álvarez-Lafuente, Roberto and Casanova, Bonaventura and Comabella, Manuel and Ramió-Torrentà, Lluís and Martínez-Rodríguez, José Enrique and Brieva, Luis and Saiz, Albert and Eichau, Sara and Cabrera-Maqueda, José María and Villarrubia, Noelia and Espiño, Mercedes and Pérez-Miralles, Francisco and Montalbán, Xavier and Tintoré, Mar and Quiroga-Varela, Ana and Domínguez-Mozo, María Inmaculada and Rodríguez-Jorge, Fernando and Chico-García, Juan Luís and Lourido, Daniel and Álvarez-Cermeño, José Carlos and Masjuan, Jaime and Costa-Frossard, Lucienne and Villar, Luisa María},
  title = {Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs},
  journal = {JAMA Neurology},
  year = {2023},
  doi = {10.1001/jamaneurol.2023.0010}
}
Kostenlos starten →